Pfizer (PFE) Equity Average (2009 - 2026)

Pfizer (PFE) has 18 years of Equity Average data on file, last reported at $88.3 billion in Q1 2026.

• Equity Average for Q1 2026 came in at $88.3 billion, down 1.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $88.3 billion (down 1.43% YoY), and the FY2025 annual result was $87.5 billion, down 3.36% from the prior year.
• Equity Average fell to $88.3 billion in Q1 2026 per PFE's latest filing, from $89.8 billion in the prior quarter.
• Over five years, Equity Average peaked at $100.3 billion in Q3 2023 and troughed at $80.1 billion in Q2 2022.
• A 5-year average of $91.2 billion and a median of $90.3 billion in 2024 frame the typical range for Equity Average.
• The sharpest annual moves came in 2022 and 2024: Equity Average surged 69.67% in 2022, then declined 9.97% in 2024.
• A 5-year view of Equity Average shows it stood at $94.4 billion in 2022, then retreated by 1.23% to $93.2 billion in 2023, then declined by 2.92% to $90.5 billion in 2024, then decreased by 0.82% to $89.8 billion in 2025, then fell by 1.67% to $88.3 billion in 2026.
• Business Quant data shows PFE's Equity Average at $88.3 billion in Q1 2026, $89.8 billion in Q4 2025, and $91.1 billion in Q3 2025.